Literature DB >> 31129915

Increased Accumulation and Retention of rhFVIIa (eptacog beta) in Knee Joints of Hemophilia A Mice Compared to Wild-Type Mice.

Jhansi Magisetty1, Usha R Pendurthi1, SubbaRao V Madhunapantula2, Jerry Grandoni3, L Vijaya Mohan Rao1.   

Abstract

Our earlier studies showed that recombinant human factor VIIa (rhFVIIa) administered intravascularly in mice disappeared rapidly from the circulation. However, a small fraction of rhFVIIa that entered extravascular remained functionally active for an extended period. The present study aims to investigate the dose-dependency of rhFVIIa accumulation and retention in mouse knee joints and test whether the hemophilic condition affects rhFVIIa sequestration in joints. Wild-type and FVIII-/- mice were injected with three doses of rhFVIIa (eptacog beta, 90, 250, and 500 μg/kg) via the tail vein. At varying times following rhFVIIa administration, blood and knee joints were collected to measure FVIIa activity and antigen levels in plasma and joint tissues. Joint tissue sections were analyzed by immunohistochemistry for the presence of rhFVIIa. Vascular permeability was assessed by either Evans Blue dye or fluorescein dextran extravasation. The study showed that rhFVIIa accumulated in knee joints of wild-type and FVIII-/- mice in a dose-dependent manner. rhFVIIa antigen and FVIIa activity could be detectable in joints for at least 7 days. Significantly higher levels of rhFVIIa accumulation were observed in knee joints of FVIII-/- mice compared with that of wild-type mice. Immunohistochemical analyses confirmed higher levels of rhFVIIa retention in FVIII-/- mice compared with wild-type mice. Additional studies showed that FVIII-/- mice were more permissible to vascular leakage. In conclusion, the present data demonstrate a dose-dependent accumulation of rhFVIIa in knee joints, and the hemophilic condition enhances the entry of rhFVIIa from circulation to the extravascular. The present data will be useful in improving rhFVIIa prophylaxis. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31129915      PMCID: PMC6682440          DOI: 10.1055/s-0039-1688907

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  30 in total

1.  Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint.

Authors:  B R Saxon; D Shanks; C B Jory; V Williams
Journal:  Thromb Haemost       Date:  2001-10       Impact factor: 5.249

2.  Prophylaxis with recombinant factor VIIa for the management of bleeding episodes during immune tolerance treatment in a boy with severe haemophilia A and high-response inhibitors.

Authors:  J Blatny; S Kohlerova; O Zapletal; V Fiamoli; M Penka; O Smith
Journal:  Haemophilia       Date:  2008-06-05       Impact factor: 4.287

Review 3.  Recombinant factor VIIa in paediatric bleeding disorders--a 2006 review.

Authors:  P Mathew; G Young
Journal:  Haemophilia       Date:  2006-09       Impact factor: 4.287

4.  Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors.

Authors:  G Young; M McDaniel; D J Nugent
Journal:  Haemophilia       Date:  2005-05       Impact factor: 4.287

5.  Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis.

Authors:  L A Valentino; N Hakobyan
Journal:  Haemophilia       Date:  2006-11       Impact factor: 4.287

6.  Recombinant factor VIIa prophylaxis in a patient with severe congenital factor VII deficiency.

Authors:  W Y Tcheng; J Donkin; S Konzal; W-Y Wong
Journal:  Haemophilia       Date:  2004-05       Impact factor: 4.287

Review 7.  Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.

Authors:  T Abshire; G Kenet
Journal:  J Thromb Haemost       Date:  2004-06       Impact factor: 5.824

8.  Prophylactic effect of recombinant factor VIIa in factor VII deficient patients.

Authors:  Natascha C J Mathijssen; Rosalinde Masereeuw; Kitty Verbeek; J Maurice Lavergne; Jean-Marc Costa; Waander L van Heerde; Irena R O Nováková
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

9.  Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors.

Authors:  B A Konkle; L S Ebbesen; E Erhardtsen; R P Bianco; T Lissitchkov; L Rusen; M A Serban
Journal:  J Thromb Haemost       Date:  2007-09       Impact factor: 5.824

10.  Prophylactic treatment of haemophilia patients with inhibitors: clinical experience with recombinant factor VIIa in European Haemophilia Centres.

Authors:  M Morfini; G Auerswald; R A Kobelt; G F Rivolta; J Rodriguez-Martorell; F A Scaraggi; C Altisent; J Blatny; A Borel-Derlon; V Rossi
Journal:  Haemophilia       Date:  2007-09       Impact factor: 4.287

View more
  2 in total

1.  Factor VIIa induces extracellular vesicles from the endothelium: a potential mechanism for its hemostatic effect.

Authors:  Kaushik Das; Shiva Keshava; Shabbir A Ansari; Vijay Kondreddy; Charles T Esmon; John H Griffin; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Blood       Date:  2021-06-17       Impact factor: 25.476

2.  Oxidative Stress Product, 4-Hydroxy-2-Nonenal, Induces the Release of Tissue Factor-Positive Microvesicles From Perivascular Cells Into Circulation.

Authors:  Shabbir A Ansari; Shiva Keshava; Usha R Pendurthi; L Vijaya Mohan Rao
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-10-08       Impact factor: 8.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.